keyword
MENU ▼
Read by QxMD icon Read
search

ANTIPLATELET AGENTS

keyword
https://www.readbyqxmd.com/read/28806011/a-primer-on-bleeding-risk-and-management-strategies-of-newer-oral-anti-platelet-agents-in-cardiovascular-disease
#1
Jimmy Yee, Vishesh Kumar, Amornpol Anuwatworn, Marian Petrasko, Adam Stys
Aspirin, the first antiplatelet agent, has been around since the 19th century, and is one of the most established drugs in history. With the improvement of coronary interventions in the past few decades, there has been more reliance on oral antiplatelet agents to reduce complications of in-stent restenosis/thrombosis. Clopidogrel was initially introduced in 1997, and within the past seven years, two additional oral antiplatelet agents have been approved by the U.S. Food and Drug Administration. With more potent antiplatelet agents comes increased risks of adverse effects...
October 2016: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/28805478/production-of-platelet-rich-plasma-gel-from-elderly-patients-under-antithrombotic-drugs-perspectives-in-chronic-wounds-care
#2
M Velier, J Magalon, A Daumas, M Cassar, P Francois, A Ghazouane, C Philandrianos, B Bertrand, C Frere, D Bernot, P Villani, F Dignat George, F Sabatier
Platelet-Rich Plasma (PRP) is an autologous biological therapy obtained by centrifuging the patient's own blood to concentrate platelets. The addition of autologous thrombin and calcium chloride to PRP allows the production of a semi-solid form called PRP gel. PRP gel is increasingly used in a variety of tissue defects and predominantly in the management of non-healing chronic wounds. The topical application of PRP gel seems promising due to the capability of platelets to store and secrete growth factors (GF), fibrin and cytokines, which are essentials for wound healing...
August 14, 2017: Platelets
https://www.readbyqxmd.com/read/28797987/continued-use-of-low-dose-aspirin-may-increase-risk-of-bleeding-after-gastrointestinal-endoscopic-submucosal-dissection-a-meta-analysis
#3
Wei Wu, Jingdi Chen, Qianshan Ding, Dongmei Yang, Honggang Yu, Jun Lin
BACKGROUND/AIMS: Endoscopic submucosal dissection has been widely accepted. At present, the number of antiplatelet (APT) users has been growing. Moreover, because of high risks of thromboembolism, some patients need to continuously receive APT agents. The relationship between hemorrhage and continuous therapy with low-dose aspirin (LDA) remains controversial. MATERIALS AND METHODS: A systematic search was conducted; studies were screened out- if data of no-anticoagulant/APT drugs use and interrupted and continued-LDA use were reported separately...
August 9, 2017: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/28797264/flavonolignans-inhibit-the-arachidonic-acid-pathway-in-blood-platelets
#4
Michal Bijak, Joanna Saluk-Bijak
BACKGROUND: Arachidonic acid metabolism by cyclooxygenase (COX) is a major pathway for blood platelets' activation, which is associated with pro-thrombotic platelet activity and the production of pro-inflammatory mediators. Inhibition of COX activity is one of the major means of anti-platelet pharmacotherapy preventing arterial thrombosis and reducing the incidence of cardiovascular events. Recent studies have presented that a silymarin (standardized extract of Milk thistle (Silybum marianum)) can inhibit the COX pathway...
August 10, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28796769/medication-related-patient-harm-in-new-zealand-hospitals
#5
Gillian Robb, Elizabeth Loe, Ashika Maharaj, Richard Hamblin, Mary E Seddon
AIM: The purpose of this study is to identify patterns of medication-related harm from a national perspective, and to use this information to inform decisions on where to focus medication safety efforts. This study updates a 2013 study using the same methodology. METHOD: District health boards (DHBs) still actively using either the Adverse Drug Event (ADE) Trigger Tool (TT) or the Global Trigger Tool (GTT), submitted two years of anonymised ADE data (1 July 2013-30 June 2015) to the Health Quality & Safety Commission (the Commission) using a standard template...
August 11, 2017: New Zealand Medical Journal
https://www.readbyqxmd.com/read/28794832/perioperative-management-and-monitoring-of-antiplatelet-agents-a-focused-review-on-aspirin-and-p2y12-inhibitors
#6
REVIEW
Michael A Mazzeffi, Khang Lee, Bradley Taylor, Kenichi A Tanaka
Platelets play pivotal roles in hemostasis as well as pathological arterial thrombosis. The combination of aspirin and a P2Y12 inhibitor has become the mainstay therapy in the ageing population with cardiovascular conditions, particularly during and after percutaneous coronary intervention. A number of novel P2Y12 inhibitors has become available in the recent years, and they markedly vary in pharmacokinetic and pharmacodynamic properties. Perioperative physicians today face a challenge of preventing hemorrhage due to platelet inhibitors, while minimizing thrombotic risks...
August 2017: Korean Journal of Anesthesiology
https://www.readbyqxmd.com/read/28789568/temporal-trends-in-the-use-of-antiplatelet-therapy-in-patients-with-acute-coronary-syndromes
#7
María Asunción Esteve-Pastor, Juan Miguel Ruíz-Nodar, Esteban Orenes-Piñero, José Miguel Rivera-Caravaca, Miriam Quintana-Giner, Andrea Véliz-Martínez, Antonio Tello-Montoliu, Vicente PerniasEscrig, Miriam Sandín Rollán, Nuria Vicente-Ibarra, Manuel Jesús MacíasVillanego, Elena Candela Sánchez, Luna Carrillo Alemán, Teresa Lozano, Mariano Valdés, Francisco Marín
BACKGROUND: Current clinical guidelines of acute coronary syndromes (ACS) recommend the use of potent antiplatelet therapy, prasugrel or ticagrelor, because both drugs consistently reduce cardiovascular events. PURPOSE: The aim of this study was to examine temporal changes in the use of optimal antiplatelet therapy in patients with ACS. METHODS: A total of 1717 consecutive patients admitted for ACS in 3 tertiary hospitals from February 2014 to December 2015 were enrolled...
January 1, 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28777978/clovamide-and-clovamide-rich-extracts-of-three-trifolium-species-as-antioxidants-and-moderate-antiplatelet-agents-in-vitro
#8
Joanna Kolodziejczyk-Czepas, Justyna Krzyżanowska-Kowalczyk, Malgorzata Sieradzka, Pawel Nowak, Anna Stochmal
This in vitro study provides a new insight into the phytochemical, antioxidant, antiplatelet and cytotoxic profiles of commercial trans-clovamide and clovamide-rich extracts, isolated from aerial parts of three Trifolium species (i.e. T. clypeatum L., T. obscurum Savi and T. squarrosum L.). Under inorganic experimental conditions, the EC50 for the investigated substances varied between 4.87 (clovamide) and 7.91 μg/ml (T. clypeatum) according to the DPPH(•) assay. The most effective 1 mM ONOO(-) scavenger was clovamide (IC50 = 19...
August 1, 2017: Phytochemistry
https://www.readbyqxmd.com/read/28776172/optimization-of-antiplatelet-therapy-in-stemi
#9
REVIEW
Abhishek Sinha, Kush Agrawal, Rahul Sakhuja
Antiplatelet therapy is an essential component of ST elevation myocardial infarction (STEMI) management. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel has previously been the standard of care for STEMI management, but the advent of newer, more potent P2Y12 inhibitors has expanded the options for the management of STEMI. As compared with clopidogrel, these newer P2Y12 agents-such as prasugrel and ticagrelor-allow for further reductions in ischemic end points, without the robust increases in bleeding seen in previous studies of antithrombotic therapies...
August 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28768848/predicting-major-bleeding-in-patients-with-noncardioembolic-stroke-on-antiplatelets-s2top-bleed
#10
Nina A Hilkens, Ale Algra, Hans-Christoph Diener, Johannes B Reitsma, Philip M Bath, Laszlo Csiba, Werner Hacke, L Jaap Kappelle, Peter J Koudstaal, Didier Leys, Jean-Louis Mas, Ralph L Sacco, Pierre Amarenco, Leila Sissani, Jacoba P Greving
OBJECTIVE: To develop and externally validate a prediction model for major bleeding in patients with a TIA or ischemic stroke on antiplatelet agents. METHODS: We combined individual patient data from 6 randomized clinical trials (CAPRIE, ESPS-2, MATCH, CHARISMA, ESPRIT, and PRoFESS) investigating antiplatelet therapy after TIA or ischemic stroke. Cox regression analyses stratified by trial were performed to study the association between predictors and major bleeding...
August 2, 2017: Neurology
https://www.readbyqxmd.com/read/28764618/hydroxychloroquine-in-the-primary-thrombosis-prophylaxis-of-antiphospholipid-antibody-positive-patients-without-systemic-autoimmune-disease
#11
D Erkan, O Unlu, S Sciascia, H M Belmont, D Ware Branch, M J Cuadrado, E Gonzalez, J S Knight, I Uthman, R Willis, Z Zhang, D Wahl, S Zuily, M G Tektonidou
Objective The objective of this study was to determine the efficacy of hydroxychloroquine (HCQ) in the primary thrombosis prevention of antiphospholipid antibody (aPL)-positive patients with no other systemic autoimmune diseases. Methods Under the auspices of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking, a multicenter, international, randomized controlled trial (RCT) was initiated, in which persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases were randomized to receive HCQ or no treatment in addition to their standard regimen...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28763790/platelets-subvert-t-cell-immunity-against-cancer-via-garp-tgf%C3%AE-axis
#12
Saleh Rachidi, Alessandra Metelli, Brian Riesenberg, Bill X Wu, Michelle H Nelson, Caroline Wallace, Chrystal M Paulos, Mark P Rubinstein, Elizabeth Garrett-Mayer, Mirko Hennig, Daniel W Bearden, Yi Yang, Bei Liu, Zihai Li
Cancer-associated thrombocytosis has long been linked to poor clinical outcome, but the underlying mechanism is enigmatic. We hypothesized that platelets promote malignancy and resistance to therapy by dampening host immunity. We show that genetic targeting of platelets enhances adoptive T cell therapy of cancer. An unbiased biochemical and structural biology approach established transforming growth factor β (TGFβ) and lactate as major platelet-derived soluble factors to obliterate CD4(+) and CD8(+) T cell functions...
May 5, 2017: Science Immunology
https://www.readbyqxmd.com/read/28762630/comparison-of-multiple-electrode-aggregometry-with-lumi-aggregometry-for-the-diagnosis-of-patients-with-mild-bleeding-disorders
#13
R Al Ghaithi, S Drake, S P Watson, N V Morgan, P Harrison
BACKGROUND: Multiple electrode aggregometry (MEA) measures changes in electrical impedance caused by platelet aggregation in whole blood. This approach is faster, more convenient and offers the advantage over light transmission aggregometry (LTA) of assessing platelet function in whole blood and reducing pre-analytical errors associated with preparation of platelet rich plasma (PRP). Several studies indicate the utility of this method in assessing platelet inhibition in individuals taking antiplatelet agents e...
August 1, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28761577/bleeding-risk-related-to-upper-gastrointestinal-endoscopic-biopsy-in-patients-receiving-antithrombotic-therapy-a-multicenter-prospective-observational-study
#14
Takafumi Yuki, Shunji Ishihara, Kazuo Yashima, Koichiro Kawaguchi, Hirofumi Fujishiro, Youichi Miyaoka, Mika Yuki, Yoshinori Kushiyama, Akiko Yasugi, Michiko Shabana, Koichirou Furuta, Kiwamu Tanaka, Masaharu Koda, Tetsuro Hamamoto, Yuichiro Sasaki, Hisao Tanaka, Teiji Yoshimura, Yoshikazu Murawaki, Hajime Isomoto, Yoshikazu Kinoshita
BACKGROUND: Although antithrombotic agents are widely used for cardiac and cerebrovascular disease prevention, they increase the risk of gastrointestinal (GI) bleeding. OBJECTIVE: To examine GI bleeding risk in association with an esophagogastroduodenoscopy (EGD) biopsy performed in patients without cessation of antithrombotic therapy. METHODS: This study was prospectively conducted at 14 centers. EGD biopsies were performed in patients receiving antithrombotic agents without cessation, as well as age- and sex-matched controls not receiving antithrombotic therapy...
2017: Current Therapeutic Research, Clinical and Experimental
https://www.readbyqxmd.com/read/28760712/glucose-impairs-aspirin-inhibition-in-platelets-through-a-nad-p-h-oxidase-signaling-pathway
#15
Gennadi Kobzar, Vilja Mardla, Nigulas Samel
Hyperglycemia has been suggested to play a role in the increased platelet resistance to antiplatelet therapy in patients with diabetes mellitus. Exposure to high glucose impairs platelet inhibition by aspirin. It has been found that antioxidant agents reduce the effect of glucose, confirming the involvement of reactive oxygen species (ROS) in the effect of glucose. The aim of the study was to examine the mechanism of ROS increase by high glucose in aspirin-treated platelets. Platelet aggregation was measured by the optical method, and the production of ROS was detected using luminol-dependent horseradish peroxidase-enhanced chemiluminescence...
July 29, 2017: Prostaglandins & Other Lipid Mediators
https://www.readbyqxmd.com/read/28759588/risk-factors-associated-with-the-development-of-seizures-among-adult-patients-treated-with-ertapenem-a-matched-case-control-study
#16
Yi-Chien Lee, Yun-Jhong Huang, Miao-Chiu Hung, Sheng-Che Hung, Chih-Yen Hsiao, Hui-Ling Cho, Li-Fen Lai, Show-Hwa Tong, Jann-Tay Wang
OBJECTIVE: The purpose of this study is to compare the characteristics of those ertapenem-treated adult patients with and without development of seizures, and identify the associated factors for the development of seizures. METHODS: This retrospective study was conducted at Chia-Yi Christian Hospital from January 2012 to December 2014. Patients developing seizures during their ertapenem treatment course were identified as case patients. Those without seizures who had received ertapenem for at least five days were considered as the pool of control patients...
2017: PloS One
https://www.readbyqxmd.com/read/28757415/study-of-the-interactions-between-edaglitazone-and-ciglitazone-with-ppar%C3%AE-and-their-antiplatelet-profile
#17
Camila Muñoz-Gutiérrez, Cesar Sepúlveda, Julio Caballero, Iván Palomo, Eduardo Fuentes
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor with an important role in lipid metabolism, inflammation and cardiovascular diseases. PPARγ ligands have inhibitory effects on platelet aggregation via the cAMP pathway, which may confer them a protective cardioprotective role. Edaglitazone and Ciglitazone are two chemically-similar thiazolidinedione (TZD) drugs that have been described as potent PPARγ agonists; however, Edaglitazone is over 100 times more potent than Ciglitazone...
July 28, 2017: Life Sciences
https://www.readbyqxmd.com/read/28752248/antiplatelet-agents-for-cancer-treatment-a-real-perspective-or-just-an-echo-from-the-past
#18
Marek Z Wojtukiewicz, Dominika Hempel, Ewa Sierko, Stephanie C Tucker, Kenneth V Honn
The association between coagulation and cancer development has been observed for centuries. However, the connection between inflammation and malignancy is also well-recognized. The plethora of evidence indicates that among multiple hemostasis components, platelets play major roles in cancer progression by providing surface and granular contents for several interactions as well as behaving like immune cells. Therefore, the anticancer potential of anti-platelet therapy has been intensively investigated for many years...
July 27, 2017: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/28751840/clinical-pathways-and-management-of-antithrombotic-therapy-in-patients-with-acute-coronary-syndrome-acs-a-consensus-document-from-the-italian-association-of-hospital-cardiologists-anmco-italian-society-of-cardiology-sic-italian-society-of-emergency-medicine
#19
Leonardo De Luca, Furio Colivicchi, Michele Massimo Gulizia, Francesco Rocco Pugliese, Maria Pia Ruggieri, Giuseppe Musumeci, Gian Alfonso Cibinel, Francesco Romeo
Antiplatelet therapy is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS). Over the last years, several studies have evaluated old and new oral or intravenous antiplatelet agents in ACS patients. In particular, research was focused on assessing superiority of two novel platelet ADP P2Y12 receptor antagonists (i.e., prasugrel and ticagrelor) over clopidogrel. Several large randomized controlled trials have been undertaken in this setting and a wide variety of prespecified and post-hoc analyses are available that evaluated the potential benefits of novel antiplatelet therapies in different subsets of patients with ACS...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28750875/chronic-kidney-disease-in-hypertensive-subjects-%C3%A2-60-years-treated-in-primary-care
#20
Betlem Salvador-González, Jordi Mestre-Ferrer, Maria Soler-Vila, Luisa Pascual-Benito, Eva Alonso-Bes, Oriol Cunillera-Puértolas
BACKGROUND: Hypertension (HT) is the second leading cause of kidney failure. In hypertensive patients with chronic kidney disease (CKD), blood pressure (BP) control is the most important intervention to minimise progression. For CKD diagnosis, standardised creatinine and estimated glomerular filtration rate (eGFR) testing by CKD-EPI is recommended. OBJECTIVES: To describe the prevalence and factors associated with a moderate decrease in eGFR (by CKD-EPI) and BP control in subjects with HT...
July 2017: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
keyword
keyword
11540
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"